Renovaro Biosciences Inc (RENB) — Cash Flow-to-Debt Ratio
Renovaro Biosciences Inc (RENB) has a Cash Flow-to-Debt Ratio of -0.06x as of June 2025, meaning its operating cash flow of $-1.81 Million could theoretically repay 0% of its total liabilities ($29.58 Million) in one year. Explore Renovaro Biosciences Inc strategic investment ratio to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Renovaro Biosciences Inc Cash Flow-to-Debt Ratio (2012–2025)
Historical debt coverage capacity for Renovaro Biosciences Inc across 14 annual periods. Also explore RENB total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Renovaro Biosciences Inc (2012–2025)
Year-by-year debt coverage analysis for Renovaro Biosciences Inc. For market capitalisation and broader financial context, see RENB market cap overview.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.35x | $-10.97 Million | $31.15 Million | ▲ +0.0% |
| 2024 | -0.35x | $-10.97 Million | $31.15 Million | ▲ +64.7% |
| 2023 | -1.00x | $-11.77 Million | $11.80 Million | ▲ +23.8% |
| 2022 | -1.31x | $-15.73 Million | $12.01 Million | ▲ +5.1% |
| 2021 | -1.38x | $-20.61 Million | $14.94 Million | ▼ -56.0% |
| 2020 | -0.88x | $-10.46 Million | $11.83 Million | ▲ +29.6% |
| 2019 | -1.26x | $-8.51 Million | $6.78 Million | ▼ -587.6% |
| 2018 | -0.18x | $-4.34 Million | $23.76 Million | ▲ +53.7% |
| 2017 | -0.39x | $-1.18 Million | $2.99 Million | ▲ +59.7% |
| 2016 | -0.98x | $-1.47 Million | $1.51 Million | ▲ +15.7% |
| 2015 | -1.16x | $-2.03 Million | $1.76 Million | ▼ -14.1% |
| 2014 | -1.01x | $-2.13 Million | $2.10 Million | ▼ -140.1% |
| 2013 | -0.42x | $-30.09K | $71.23K | ▲ +53.9% |
| 2012 | -0.92x | $-24.95K | $27.23K | — |